When CA170 was combined with a peptide vaccine that specifically targets Kras, which is the driver gene in VC-induced tumors, tumor inhibition was almost 80% when compared to adjuvant-treated controls (Fig. 1). This evidence concerns the gene KRAS and neoplasm.